AVEO Pharmaceuticals Inc. (AVEO)

1.99
NASDAQ : Health Technology
Prev Close 1.99
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.49 / 3.59
Avg Volume 2.82M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 258.21M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

2 Small Biotech Stocks That Insiders Are Buying

2 Small Biotech Stocks That Insiders Are Buying

Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.

AVEO Oncology To Present At The 30th Annual Piper Jaffray Healthcare Conference

AVEO Oncology To Present At The 30th Annual Piper Jaffray Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.

AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To German Commercialization Of FOTIVDA®

AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To German Commercialization Of FOTIVDA®

AVEO Oncology (NASDAQ: AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma.

AVEO Reports Third Quarter 2018 Financial Results And Provides Business Update

AVEO Reports Third Quarter 2018 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2018 and provided a business update.

July 2019 Options Now Available For AVEO Pharmaceuticals (AVEO)

July 2019 Options Now Available For AVEO Pharmaceuticals (AVEO)

Investors in AVEO Pharmaceuticals Inc saw new options begin trading today, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 254 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AVEO Oncology Announces Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma Meets Primary Endpoint

AVEO Oncology Announces Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma Meets Primary Endpoint

AVEO Oncology (NASDAQ: AVEO) today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company's Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA ®) to sorafenib in 351 subjects...

AVEO Oncology And EUSA Pharma Announce Updated Interim Results From Phase 2 Portion Of The TiNivo Study In Renal Cell Carcinoma

AVEO Oncology And EUSA Pharma Announce Updated Interim Results From Phase 2 Portion Of The TiNivo Study In Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of updated interim results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA ®) in combination with intravenous (IV)...

AVEO Oncology To Present Updated Interim Results From The Phase 2 Portion Of The TiNivo Study Of Tivozanib And Nivolumab (OPDIVO®) In RCC At The ESMO 2018 Annual Congress

AVEO Oncology To Present Updated Interim Results From The Phase 2 Portion Of The TiNivo Study Of Tivozanib And Nivolumab (OPDIVO®) In RCC At The ESMO 2018 Annual Congress

AVEO Oncology (NASDAQ:AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO ®) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO)...

AVEO Oncology Announces Initiation Of Topline Analysis Of Phase 3 TIVO-3 Trial

AVEO Oncology Announces Initiation Of Topline Analysis Of Phase 3 TIVO-3 Trial

AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated topline analysis of the phase 3 TIVO-3 clinical trial on the unanimous recommendation of the independent TIVO-3 Study Steering Committee, and after notice to the FDA.

Interesting AVEO Put And Call Options For November 16th

Interesting AVEO Put And Call Options For November 16th

Investors in AVEO Pharmaceuticals Inc saw new options begin trading this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

First Week Of January 2021 Options Trading For AVEO Pharmaceuticals (AVEO)

First Week Of January 2021 Options Trading For AVEO Pharmaceuticals (AVEO)

Investors in AVEO Pharmaceuticals Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AVEO Oncology To Participate In Upcoming Conferences

AVEO Oncology To Participate In Upcoming Conferences

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer, will participate in the following investor conferences: B.

AVEO Announces Pricing Of $5.7 Million Public Offering Of Common Stock

AVEO Announces Pricing Of $5.7 Million Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.

AVEO Announces Proposed Offering Of Common Stock

AVEO Announces Proposed Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

AVEO Announces Acceptance Of CANbridge Investigational New Drug Application For CAN017 (AV-203) Trial In Esophageal Squamous Cell Cancer (ESCC) In China

AVEO Announces Acceptance Of CANbridge Investigational New Drug Application For CAN017 (AV-203) Trial In Esophageal Squamous Cell Cancer (ESCC) In China

AVEO Oncology (Nasdaq: AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences' Investigational New Drug (IND) Application for a Phase Ib/III clinical trial of CAN017 (AV-203), AVEO's clinical-stage...

AVEO Reports Second Quarter 2018 Financial Results And Provides Business Update

AVEO Reports Second Quarter 2018 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2018 and provided a business update.

AVEO Oncology To Present At The Canaccord Genuity 38th Annual Growth Conference

AVEO Oncology To Present At The Canaccord Genuity 38th Annual Growth Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8, 2018 at 4:30 p.

AVEO Oncology Added To The Russell 2000, Russell 3000, And Russell Microcap Indexes

AVEO Oncology Added To The Russell 2000, Russell 3000, And Russell Microcap Indexes

AVEO Oncology (NASDAQ: AVEO) today announced that it has been added to the Russell 2000 ®, Russell 3000 ®, and Russell Microcap ® Indexes, effective after the U.

AVEO Reports First Quarter 2018 Financial Results And Provides Business Update

AVEO Reports First Quarter 2018 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2018 and provided a business update.

Interesting AVEO Put And Call Options For June 15th

Investors in AVEO Pharmaceuticals Inc saw new options begin trading this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: Needham & Company's 17th Annual Healthcare...

AVEO Oncology Announces Publication Of Long-term Follow-up Results From TIVO-1 Extension Study (Study 902) In TKI Refractory RCC

AVEO Oncology Announces Publication Of Long-term Follow-up Results From TIVO-1 Extension Study (Study 902) In TKI Refractory RCC

AVEO Oncology (NASDAQ: AVEO) today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib (FOTIVDA ®) as second-line treatment in advanced renal cell...

AVEO Reports Full Year 2017 Financial Results And Provides Business Update

AVEO Reports Full Year 2017 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2017 and provided a business update.

AVEO Oncology To Present At The Cowen And Company 38th Annual Health Care Conference

AVEO Oncology To Present At The Cowen And Company 38th Annual Health Care Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38 th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at...

AVEO Announces EUSA Pharma Granted Positive NICE Recommendation For FOTIVDA® (tivozanib) As First Line Treatment For Advanced Renal Cell Carcinoma

AVEO Announces EUSA Pharma Granted Positive NICE Recommendation For FOTIVDA® (tivozanib) As First Line Treatment For Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom's National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending FOTIVDA ® (tivozanib) for...

AVEO Oncology And EUSA Pharma Announce Encouraging Preliminary Results From Phase 2 Portion Of The TiNivo Study In Renal Cell Carcinoma

AVEO Oncology And EUSA Pharma Announce Encouraging Preliminary Results From Phase 2 Portion Of The TiNivo Study In Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA ®) in...

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: LEERINK Partners 7th Annual Global Healthcare...

TheStreet Quant Rating: D- (Sell)